Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies INDIANAPOLIS, July 27, 2023. Eli Lilly announced results of Mounjaro (tirzepatide) phase 3 studies in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. SURMOUNT-3 and SURMOUNT-4 met all primary and key secondary objectives for tirzepatide compared to placebo. Across […]
